For the second quarter of 2026, analysts expect Quantum-Si to report a consensus revenue of $0.30 million and an EPS loss of $0.13, while the stock currently trades near $0.81 against a median price target of $2.50.
The primary focus for investors remains the commercial adoption and placement rate of the Platinum® protein sequencing platform as the company seeks to build market share in the proteomics industry.
Market participants are closely monitoring the company's ability to transition from a development-stage entity to generating consistent product revenue while managing a significant cash burn rate. Management's commentary regarding consumable pull-through and new institutional partnerships will be critical in assessing the long-term scalability of their semiconductor-based technology.